ClinicalTrials.gg
Status unknownNCT03105505Updated Jan 30, 2018

The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis

A Phase 4 interventional study of Permethrin 5% and Synthomycine 5% in Inflammation of the Eyelids, sponsored by Barzilai Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by Barzilai Medical Center · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to investigate the effect of Permethrin 5% treatment on Signs and symptoms of Demodex-blepharitis in comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%) .

Read the detailed description

3 arms study. 75 patient total, 25 patients in each group.

Group A (study group) patients will apply facially Permethrin 5% every night for 3 months.

Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months.

Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months

Follow up Evaluation will be made after one week, one month, two months, three months, 4 months and half a year.

02

Conditions studied

  • Inflammation of the Eyelids
03

In context

Lead sponsor

Barzilai Medical Center is the lead sponsor of 26 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (Age ≥18Y) individuals clinically diagnosed with Demodex- blepharitis.

Exclusion criteria

Exclusion Criteria:

  • Known sensitivity to all study medications or components. Pregnant women and individuals deemed unfit to provide . Systemic use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Permethrin 5%

    Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.

    Drug: Permethrin 5%

  • Active comparator
    Synthomycine 5%,

    Contains chloramphenicol 5%.

    Drug: Synthomycine 5%

  • Active comparator
    Fusidic Acid 1%

    Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.

    Drug: Fusidic Acid 1% M/R Eye Drops

Interventions

  • Facial skin application once a night for 3 months.

  • DrugSynthomycine 5%

    Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.

  • DrugFusidic Acid 1% M/R Eye Drops

    Drug page: Fusidic Acid

    viscous eye drops application once a night for 3 months.

06

What researchers measure

Primary outcomes

  1. Decrease in demodex infestation in group A (permethrin 5%).

    significant decrease in demodex infestation in comparison to group B and C.

    Time frame: 2 months

  2. Improvement in symptoms and complaints in group A.

    OSDI Questionnaires that describe the severity of the ocular surface disease condition are filled in each visit.

    Time frame: 2 months

07

Study locations

1 site
  • Barzilai Medical Center
    Ashqelon, 78278, Israel
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Sep 2018, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Apr 10, 2017
StartActual
Apr 28, 2017
Primary completionEst.
Sep 2018
CompletionEst.
Sep 2018
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03105505
Lead sponsor
Barzilai Medical Center
Responsible party
Igor Kaiserman (Prof Igor Kaiserman, Barzilai Medical Center) — Principal investigator
First posted
Apr 10, 2017
Start date
Apr 28, 2017
Primary completion
Sep 2018 (estimated)
Completion
Sep 2018 (estimated)
Last update
Jan 30, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Permethrin · Fusidic Acid

Start the discussion